Literature DB >> 23617438

Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.

Pauline B Van de Weert-van Leeuwen1, Marit A Van Meegen, Jennifer J Speirs, D J Pals, Suzan H M Rooijakkers, Cornelis K Van der Ent, Suzanne W J Terheggen-Lagro, Hubertus G M Arets, Jeffrey M Beekman.   

Abstract

Cystic fibrosis (CF) is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, and is characterized by chronic pulmonary infections. The mechanisms underlying chronic infection and inflammation remain incompletely understood. Mutant CFTR in nonepithelial tissues such as immune cells has been suggested to contribute to infection, inflammation, and the resultant lung disease. However, much controversy still exists regarding the intrinsic role of CFTR in immune cells, especially phagocytes. Therefore, we investigated CFTR expression and function in neutrophils and monocytes isolated from human peripheral blood. CFTR function was assessed by comparing non-CF and CF cells, before and after the chemical inhibition of CFTR. We found CFTR protein expression in monocytes, but this expression was limited or undetectable in neutrophils. Furthermore, the phagocytosis and intracellular killing of Pseudomonas aeruginosa was reduced in CF monocytes, and impaired phagocyte effector mechanisms were phenocopied in non-CF monocytes upon the pharmacological inhibition of CFTR. Reduced phagocytosis in CF monocytes relied on the complement-dependent opsonization of Pseudomonas aeruginosa, and was also observed in the context of latex particles labeled with purified C3b. In mechanistic terms, we observed that CFTR function in monocytes is required for the optimal expression of CD11b. We observed no role for CFTR in neutrophil-mediated phagocytosis. These data support an intrinsic role for CFTR in monocytes, and suggest that CFTR-dependent alterations in complement-mediated interactions between Pseudomonas aeruginosa and monocytes may contribute to enhanced susceptibility to infection in patients with CF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23617438     DOI: 10.1165/rcmb.2012-0502OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  32 in total

1.  Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.

Authors:  Jonas C Schupp; Sara Khanal; Jose L Gomez; Maor Sauler; Taylor S Adams; Geoffrey L Chupp; Xiting Yan; Sergio Poli; Yujiao Zhao; Ruth R Montgomery; Ivan O Rosas; Charles S Dela Cruz; Emanuela M Bruscia; Marie E Egan; Naftali Kaminski; Clemente J Britto
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

Review 2.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

3.  The Phagocytosis of Blood Leukocytes from Cystic Fibrosis Patients is not Impaired in General.

Authors:  Laura Leuer; Angelika Krill; Heinrike Wilkens; Gudrun Wagenpfeil; Markus Bischoff; Carola Meier; Robert Bals; Thomas Tschernig
Journal:  Lung       Date:  2019-11-09       Impact factor: 2.584

Review 4.  Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Authors:  Maaike Cockx; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

5.  Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.

Authors:  Nicholas W Keiser; Susan E Birket; Idil A Evans; Scott R Tyler; Adrianne K Crooke; Xingshen Sun; Weihong Zhou; Joseph R Nellis; Elizabeth K Stroebele; Kengyeh K Chu; Guillermo J Tearney; Mark J Stevens; J Kirk Harris; Steven M Rowe; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

6.  Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.

Authors:  Roxanna Barnaby; Katja Koeppen; Amanda Nymon; Thomas H Hampton; Brent Berwin; Alix Ashare; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-16       Impact factor: 5.464

Review 7.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

8.  Glutaredoxin-1 attenuates S-glutathionylation of the death receptor fas and decreases resolution of Pseudomonas aeruginosa pneumonia.

Authors:  Vikas Anathy; Scott W Aesif; Sidra M Hoffman; Jenna L Bement; Amy S Guala; Karolyn G Lahue; Laurie W Leclair; Benjamin T Suratt; Carlyne D Cool; Matthew J Wargo; Yvonne M W Janssen-Heininger
Journal:  Am J Respir Crit Care Med       Date:  2014-02-15       Impact factor: 21.405

Review 9.  Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.

Authors:  Rustin R Lovewell; Yash R Patankar; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-24       Impact factor: 5.464

Review 10.  Cystic Fibrosis Lung Immunity: The Role of the Macrophage.

Authors:  Emanuela M Bruscia; Tracey L Bonfield
Journal:  J Innate Immun       Date:  2016-06-24       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.